Mylan Receives Approval for Biosimilar in India; Reaches Settlement with Teva on Copaxone - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mylan Receives Approval for Biosimilar in India; Reaches Settlement with Teva on Copaxone


The generic-drug/specialty pharmaceutical company Mylan and the Indian biopharmaceutical company Biocon have received approval for a biosimilar version of trastuzumab in India. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name Hertraz.

Trastuzumab is one of five biologic products Mylan is developing in partnership with Biocon. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the United States, Canada, Japan, Australia, New Zealand, and countries in the European Union and European Free Trade Association and co-exclusive commercialization rights with Biocon for the product in India. Mylan expects to launch trastuzumab in India early in 2014.

In other news, Mylan reports that it and Teva Pharmaceutical Industries have agreed to settle and dismiss pending patent litigation involving Teva's e multiple-sclerosis drug Copaxone (glatiramer acetate) in the United Kingdom, the Netherlands, and France relating to noninfringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential.

Source: Mylan and Teva Pharmaceutical Industries

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here